SCHEMBL22232177

SCHEMBL22232177

Cc1ccc(Nc2cc(C)cc(N)c2Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 6/20 0.53
MAPT P10636 5/20 0.53
TDP1 Q9NUW8 5/20 0.53
NPC1 O15118 4/20 0.46
KDM4E B2RXH2 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GFER P55789 1/20 0.46
RAPGEF4 Q8WZA2 1/20 0.44
L3MBTL1 Q9Y468 4/20 0.42
ALDH1A1 P00352 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
POLB P06746 1/20 0.42
RECQL P46063 1/20 0.42
CASP6 P55212 1/20 0.42
ELAVL1 Q15717 1/20 0.42
EGFR P00533 1/20 0.41
RAB9A P51151 4/20 0.40
HPGD P15428 2/20 0.39
HTT P42858 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29454181 1.00 GAA (0.53) GAAMAPTTDP1NPC1KDM4E
SCHEMBL29454186 0.91 NPC1 (0.44) GAAMAPTTDP1NPC1KDM4E
SCHEMBL22232474 0.91 NPC1 (0.44) GAAMAPTTDP1NPC1KDM4E
SCHEMBL22231721 0.88 BPTF (0.41) GAAMAPTTDP1NPC1KDM4E
SCHEMBL29454349 0.88 BPTF (0.41) GAAMAPTTDP1NPC1KDM4E
SCHEMBL22231911 0.88 GAA (0.50) GAAMAPTTDP1NPC1KDM4E
SCHEMBL29454250 0.88 GAA (0.50) GAAMAPTTDP1NPC1KDM4E
SCHEMBL29454091 0.85 MAPT (0.39) GAAMAPTTDP1NPC1KDM4E
SCHEMBL22232357 0.85 MAPT (0.53) GAAMAPTTDP1NPC1KDM4E
SCHEMBL29454142 0.85 MAPT (0.53) GAAMAPTTDP1NPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4647426-A2 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2025-11-12 EP claimed
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-24 US claimed
EP-3911629-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2021-11-24 EP claimed
WO-2020148617-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2020-07-23 WO claimed
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-24 US disclosed
EP-3911629-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2021-11-24 EP disclosed
WO-2020148617-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2020-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF H1-3, PRMT7, PFAS GAA 1080/4885MAPT 3811/4885TDP1 1133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.